

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CHINA PIONEER PHARMA HOLDINGS LIMITED**

**中国先锋医药控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 01345)**

### **ANNOUNCEMENT PURSUANT TO RULE 3.7 OF THE TAKEOVERS CODE, RULE 13.09 OF THE LISTING RULES AND INSIDE INFORMATION PROVISIONS UNDER PART XIVA OF THE SECURITIES AND FUTURES ORDINANCE IN RELATION TO CESSATION OF DISCUSSION IN RESPECT OF POSSIBLE TRANSACTION**

This announcement is made by China Pioneer Pharma Holdings Limited (the “**Company**”) pursuant to Rule 3.7 of the Hong Kong Code on Takeovers and Mergers (the “**Takeovers Code**”), Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to (i) the announcement of the Company dated 8 November 2016 in relation to the discussions between Pioneer Pharma (BVI) Co., Ltd., the controlling shareholder of the Company (“**Pioneer Pharma**”), and certain third parties regarding the possible sale of some or all of Pioneer Pharma’s shareholding interests in the Company (the “**Possible Transaction**”); and (ii) the subsequent monthly update announcements of the Company dated 8 December 2016, 6 January, 8 February, 8 March, 7 April, 8 May and 8 June 2017 respectively regarding the Possible Transaction.

The Company wishes to inform its shareholders and potential investors that as informed by Pioneer Pharma, Pioneer Pharma has ceased its discussion with potential purchasers in respect of the Possible Transaction. Pioneer Pharma has not entered into any formal or legally binding sale and purchase agreement in respect of the Possible Transaction. Accordingly, the Company will cease to publish further monthly announcement in respect of the progress of the Possible Transaction, which would otherwise be required under Rule 3.7 of the Takeovers Code.

For the purpose of the Takeovers Code, the offer period in respect of the Possible Transaction is closed on the date of this announcement.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares and other securities of the Company.**

By Order of the Board  
**China Pioneer Pharma Holdings Limited**  
**Li Xinzhou**  
Chairman

Hong Kong, 23 June 2017

*As at the date of this announcement, the Directors are Mr. LI Xinzhou and Mr. ZHU Mengjun as executive Directors, Mr. WANG Yinping and Mr. WU Mijia as non-executive Directors and Mr. XU Zhonghai, Mr. LAI Chanshu and Mr. WONG Chi Hung, Stanley as independent non-executive Directors.*

*The directors of the Company jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statements in this announcement misleading.*